Mohammad Hojat Farsangi

Publikationer
Populärvetenskap och samverkan

Artiklar

Journal article: PHARMACEUTICAL RESEARCH. 2024;41(2):407-408
Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model (Retraction of Vol 39, Pg 1851, 2022)
Barshidi A; Karpisheh V; Noukabadi FK; Kiani FK; Mohammadi M; Afsharimanesh N; Ebrahimi F; Kiaie SH; Navashenaq JG; Hojjat-Farsangi M; Zolbanin NM; Mahmoodpoor A; Hassannia H; Nami S; Jalali P; Jafari R; Jadidi-Niaragh F
Article: MICROCHIMICA ACTA. 2023;190(10):418
Detection of receptor tyrosine kinase-orphan receptor-2 using an electrochemical immunosensor modified with electrospun nanofibers comprising polyvinylpyrrolidone, soy, and gold nanoparticles
Maleki F; Razmi H; Rashidi M-R; Yousefi M; Ramazani S; Ghorbani M; Hojjat-Farsangi M; Shahpasand K
Article: CELL COMMUNICATION AND SIGNALING. 2023;21(1):188
Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide.
Khodakarami A; Kashani MA; Nazer A; Kheshti AM; Rashidi B; Karpisheh V; Masjedi A; Abolhasani S; Izadi S; Bagherifar R; Hejazian SS; Mohammadi H; Movassaghpour A; Feizi AAH; Hojjat-Farsangi M; Jadidi-Niaragh F
Article: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023;121:110463
Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model
Ramezani-Aliakbari K; Khaki-Bakhtiarvand V; Mahmoudian J; Asgarian-Omran H; Shokri F; Hojjat-Farsangi M; Jeddi-Tehrani M; Shabani M
Article: PHARMACEUTICS. 2023;15(4):1148
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: REPRODUCTIVE SCIENCES. 2023;30(4):1186-1197
Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women
Pourakbari R; Parhizkar F; Soltani-Zangbar MS; Samadi P; Zamani M; Aghebati-Maleki L; Motavalli R; Mahmoodpoor A; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Danaii S; Yousefi M
Article: IUBMB LIFE. 2023;75(3):257-278
The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia
Abolhasani S; Hejazian SS; Karpisheh V; Khodakarami A; Mohammadi H; Navashenaq JG; Hojjat-Farsangi M; Jadidi-Niaragh F
Article: CANCER NANOTECHNOLOGY. 2022;13(1):7
Early stage evaluation of colon cancer using tungsten disulfide quantum dots and bacteriophage nano-biocomposite as an efficient electrochemical platform
Pourakbari R; Yousefi M; Khalilzadeh B; Irani-nezhad MH; Khataee A; Aghebati-Maleki L; Soleimanian A; Kamrani A; Chakari-Khiavi F; Abolhasan R; Motallebnezhad M; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Rashidi M-R
Article: INTERNATIONAL IMMUNOPHARMACOLOGY. 2022;113(Pt B):109470
Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model
Bakhtiarvand VK; Akbari KR-A; Jalali SA; Hojjat-Farsangi M; Jeddi-Tehrani M; Shokri F; Shabani M
Article: PROTEIN EXPRESSION AND PURIFICATION. 2022;200:106153
Cloning, expression and characterization of a peptibody to deplete myeloid derived suppressor cells in a murine mammary carcinoma model
Akbari KR-A; Khaki-Bakhtiarvand V; Mahmoudian J; Asgarian-Omran H; Shokri F; Hojjat-Farsangi M; Jeddi-Tehrani M; Shabani M
Article: LIFE SCIENCES. 2022;309:121008
Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses
Adibfar S; Masjedi A; Nazer A; Rashidi B; Karpisheh V; Izadi S; Hassannia H; Navashenaq JG; Mohammadi H; Hojjat-Farsangi M; Tarokhian H; Jadidi-Niaragh F
Article: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY. 2022;77:103868
Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles
Feizi AAH; Vakili-Samiani S; Karpisheh V; Masjedi A; Izadi S; Adibfar S; Nikkhoo A; Hojjat-Farsangi M; Atyabi F; Khanghah OJ; Movassaghpour AA; Solali S; Yousefi M; Jadidi-Niaragh F
Article: MOLECULAR BIOLOGY REPORTS. 2022;49(11):10183-10193
Evaluation of CD39, CD73, HIF-1α, and their related miRNAs expression in decidua of preeclampsia cases compared to healthy pregnant women
Yousefzadeh Y; Soltani-Zangbar MS; Kalafi L; Tarbiat A; Farid SS; Aghebati-Maleki L; Parhizkar F; Danaii S; Taghavi S; Jadidi-Niaragh F; Kafil HS; Mahmoodpoor A; Heris JA; Hojjat-Farsangi M; Yousefi M
Article: PHARMACEUTICS. 2022;14(10):2238
A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Osterborg A; Hojjat-Farsangi M; Mellstedt H
Journal article: PHARMACEUTICAL RESEARCH. 2022;39(8):1851-1866
Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model (Retracted Article)
Barshidi A; Karpisheh V; Noukabadi FK; Kiani FK; Mohammadi M; Afsharimanesh N; Ebrahimi F; Kiaie SH; Navashenaq JG; Hojjat-Farsangi M; Zolbanin NM; Mahmoodpoor A; Hassannia H; Nami S; Jalali P; Jafari R; Jadidi-Niaragh F
Article: HUMAN IMMUNOLOGY. 2022;83(8-9):628-636
Expression level of immune checkpoint inhibitory factors in preeclampsia
Madadi S; Mohammadinejad S; Alizadegan A; Hojjat-Farsangi M; Dolati S; Kafil HS; Jadidi-Niaragh F; Soltani-Zangbar MS; Motavalli R; Etemadi J; Eghbal-Fard S; Aghebati-Maleki L; Danaii S; Taghavi S; Yousefi M
Article: IMMUNOLOGICAL INVESTIGATIONS. 2022;51(4):1023-1038
TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4⁺ T cells in Preeclampsia Patients
Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
Article: IMMUNOLOGICAL INVESTIGATIONS. 2022;51(4):1039-1059
Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems
Sarvarian P; Samadi P; Gholipour E; Shams Asenjan K; Hojjat-Farsangi M; Motavalli R; Motavalli Khiavi F; Yousefi M
Article: VIRAL IMMUNOLOGY. 2021;34(8):531-541
Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection
Asadi-Asadabad S; Sarvnaz H; Amiri MM; Mobini M; Khoshnoodi J; Hojjat-Farsangi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
Article: INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2021;186:849-863
Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo
Khesht AMS; Karpisheh V; Gilan PS; Melnikova LA; Zekiy AO; Mohammadi M; Hojjat-Farsangi M; Zolbanin NM; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
Article: EJHAEM. 2021;2(3):498-502
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1⁺ CLL cells
Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: LIFE SCIENCES. 2021;275:119369
Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression
Joshi N; Hajizadeh F; Dezfouli EA; Zekiy AO; Afjadi MN; Mousavi SM; Hojjat-Farsangi M; Karpisheh V; Mahmoodpoor A; Hassannia H; Dolati S; Mohammadi H; Yousefi M; Jadidi-Niaragh F
Article: CELL DEATH AND DISEASE. 2021;12(6):577
Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung
Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Article: CYTOKINE. 2021;141:155452
Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy
Motavalli R; Etemadi J; Soltani-Zangbar MS; Ardalan M-R; Kahroba H; Roshangar L; Nouri M; Aghebati-Maleki L; Khiavi FM; Abediazar S; Mehdizadeh A; Hojjat-Farsangi M; Mahmoodpoor A; Kafil HS; Zolfaghari M; Heris JA; Yousefi M
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2021;17(1):92-97
An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein
Sheikhi A; Hojjat-Farsangi M
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99
Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2020;235(12):10068-10080
Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses
Ghasemi-Chaleshtari M; Kiaie SH; Irandoust M; Karami H; Afjadi MN; Ghani S; Vanda NA; Sede MJG; Ahmadi A; Masjedi A; Hassannia H; Atyabi F; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
Article: PATHOLOGY RESEARCH AND PRACTICE. 2020;216(12):153247
EP4 receptor as a novel promising therapeutic target in colon cancer
Karpisheh V; Joshi N; Zekiy AO; Beyzai B; Hojjat-Farsangi M; Namdar A; Edalati M; Jadidi-Niaragh F
Article: CLINICA CHIMICA ACTA. 2020;510:203-210
Immunoreactivity pattern of monoclonal antibodies against Hepatitis B vaccine with global Hepatitis B virus genotypes
Golsaz-Shirazi F; Asadi-Asadabad S; Sarvnaz H; Amiri MM; Hojjat-Farsangi M; Chudy M; Jeddi-Tehrani M; Shokri F
Article: JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 2020;142:103182
Intrauterine administration of autologous hCG- activated peripheral blood mononuclear cells improves pregnancy outcomes in patients with recurrent implantation failure; A double-blind, randomized control trial study
Pourmoghadam Z; Soltani-Zangbar MS; Sheikhansari G; Azizi R; Eghbal-Fard S; Mohammadi H; Siahmansouri H; Aghebati-Maleki L; Danaii S; Mehdizadeh A; Hojjat-Farsangi M; Motavalli R; Yousefi M
Article: INTERNATIONAL IMMUNOPHARMACOLOGY. 2020;87:106806
IL-10-producing B cells play important role in the pathogenesis of recurrent pregnancy loss
Danaii S; Ghorbani F; Ahmadi M; Abbaszadeh H; Koushaeian L; Soltani-Zangbar MS; Mehdizadeh A; Hojjat-Farsangi M; Kafil HS; Aghebati-Maleki L; Yousefi M
Article: NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE. 2020;29:102240
Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
Masjedi A; Ahmadi A; Ghani S; Malakotikhah F; Afjadi MN; Irandoust M; Kiani FK; Asl SH; Atyabi F; Hassannia H; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
Article: ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2020;21(7):1867-1875
Toxicity of Saffron Extracts on Cancer and Normal Cells: A Review Article.
Shakeri M; Hashemi Tayer A; Shakeri H; Sotoodeh Jahromi A; Moradzadeh M; Hojjat-Farsangi M
Article: BIOMEDICINES. 2020;8(6):E170-170
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2020;149:487-500
Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression
Masjedi A; Ahmadi A; Atyabi F; Farhadi S; Irandoust M; Khazaei-Poul Y; Chaleshtari MG; Fathabad ME; Baghaei M; Haghnavaz N; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Sabz G; Hasanzadeh S; Jadidi-Niaragh F
Journal article: GENE REPORTS. 2020;18:100552
Identification of genes and miRNAs associated with angiogenesis, metastasis, and apoptosis in colorectal cancer
Pourakbari R; Mousavishenas MH; Kamrani A; Dolati S; Abbaszadeh H; Zamani M; Yaghoubi Y; Hashemzadeh S; Ahmadi M; Hojjat-Farsangi M; Mehdizadeh A; Yousefi M
Article: IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY. 2020;19(1):56-64
The Association between Inflammatory Cytokines and miRNAs with Slow Coronary Flow Phenomenon
Danaii S; Shiri S; Dolati S; Ahmadi M; Ghahremani-Nasab L; Amiri A; Kamrani A; Kafil HS; Chakari-Khiavi F; Hojjat-Farsangi M; Mahdavi AM; Mehdizadeh A; Yousefi M
Article: IMMUNOLOGY. 2020;159(1):75-87
Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Article: AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 2019;82(4):e13170
Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome
Sheikhansari G; Soltani-Zangbar MS; Pourmoghadam Z; Kamrani A; Azizi R; Aghebati-Maleki L; Danaii S; Koushaeian L; Hojat-Farsangi M; Yousefi M
Article: PROSTAGLANDINS AND OTHER LIPID MEDIATORS. 2019;144:106338
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer
Karpisheh V; Nikkhoo A; Hojjat-Farsangi M; Namdar A; Azizi G; Ghalamfarsa G; Sabz G; Yousefi M; Yousefi B; Jadidi-Niaragh F
Article: INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2019;133:436-445
Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway
Masjedi A; Hassannia H; Atyabi F; Rastegari A; Hojjat-Farsangi M; Namdar A; Soleimanpour H; Azizi G; Nikkhoo A; Ghalamfarsa G; Mirshafiey A; Jadidi-Niaragh F
Article: JOURNAL OF CELLULAR BIOCHEMISTRY. 2019;120(6):9300-9314
Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer
Nikkhoo A; Rostami N; Hojjat-Farsangi M; Azizi G; Yousefi B; Ghalamfarsa G; Jadidi-Niaragh F
Article: JOURNAL OF CELLULAR BIOCHEMISTRY. 2019;120(6):8863-8883
Promising immunotherapy: Highlighting cytokine-induced killer cells
Shirjang S; Alizadeh N; Mansoori B; Mahmoodpoor A; Kafil HS; Hojjat-Farsangi M; Yousefi M
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2019;234(4):5106-5116
The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia
Eghbal-Fard S; Yousefi M; Heydarlou H; Ahmadi M; Taghavi S; Movasaghpour A; Jadidi-Niaragh F; Yousefi B; Dolati S; Hojjat-Farsangi M; Rikhtegar R; Nouri M; Aghebati-Maleki L
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2019;234(4):4924-4933
Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities
Vahid SA; Ghaebi M; Ahmadi M; Nouri M; Danaei S; Aghebati-Maleki L; Ardehaie RM; Yousefi B; Hakimi P; Hojjat-Farsangi M; Rikhtegar R; Yousefi M
Article: AMERICAN JOURNAL OF SURGICAL PATHOLOGY. 2019;43(3):409-421
Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior
Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Soderkvist P; Gimm O; Larsson C; Juhlin CC
Article: AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 2019;81(3):e13086
Metabolic syndrome mediates proinflammatory responses of inflammatory cells in preeclampsia
Jabalie G; Ahmadi M; Koushaeian L; Eghbal-Fard S; Mehdizadeh A; Kamrani A; Abdollahi-Fard S; Farzadi L; Hojjat- Farsangi M; Nouri M; Yousefi M
Article: IMMUNOLOGY LETTERS. 2018;204:16-22
Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population
Hashemi V; Farrokhi AS; Tanomand A; Babaloo Z; Hojjat-Farsangi M; Anvari E; Tahoori M-T; Ezzeddini R; Hosseini A; Gharibi T; Ghalamfarsa G; Jadidi-Niaragh F
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2018;233(10):7165-7177
Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice
Ghalamfarsa G; Rastegari A; Atyabi F; Hassannia H; Hojjat-Farsangi M; Ghanbari A; Anvari E; Mohammadi J; Azizi G; Masjedi A; Yousefi M; Yousefi B; Hadjati J; Jadidi-Niaragh F
Article: LEUKEMIA. 2018;32(10):2291-2295
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Journal article: PAKISTAN JOURNAL OF MEDICAL AND HEALTH SCIENCES. 2018;12(2):880-883
Serum Levels of β2-Microglobulin and High Sensitive C-reactive Protein in ST-Elevated and Non.ST-Elevated Myocardial Infarction
Shojael M; Erfanian S; Taghipour N; Jahromia AS; Khoshfetrat M; Madani A; Rahmdel M; Hojjat-Farsangi M
Article: PLOS ONE. 2018;13(6):e0198038
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: ANTIVIRAL RESEARCH. 2017;144:153-163
Construction of a hepatitis B virus neutralizing chimeric monoclonal. antibody recognizing escape mutants of the viral surface antigen (HBsAg)
Golsaz-Shirazi F; Amiri MM; Farid S; Bahadori M; Bohne F; Altstetter S; Wolff L; Kazemi T; Khoshnoodi J; Hojjat-Farsangi M; Chudy M; Jeddi-Tehrani M; Protzer U; Shokri F
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: GLOBAL JOURNAL OF HEALTH SCIENCE. 2015;8(6):41-46
Lack of Association Between rs17568 Polymorphism in OX40 Gene and Myocardial Infarction, Southern of Iran.
Maalhagh M; Shojaei M; Erfanian S; Sotoodeh Jahromi A; Sanie MS; Yusefi A; Zabetian H; Hakimelahi H; Madani A; Hojjat-Farsangi M
Article: GLOBAL JOURNAL OF HEALTH SCIENCE. 2015;8(6):25-32
Association of Tumor Growth Factor-β and Interferon-γ Serum Levels With Insulin Resistance in Normal Pregnancy.
Sotoodeh Jahromi A; Sanie MS; Yusefi A; Zabetian H; Zareian P; Hakimelahi H; Madani A; Hojjat-Farsangi M
Article: PLOS ONE. 2015;10(11):e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: IMMUNOLOGY. 2014;143(3):341-353
Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling.
Shabani M; Bayat AA; Jeddi-Tehrani M; Rabbani H; Hojjat-Farsangi M; Ulivieri C; Amirghofran Z; Baldari CT; Shokri F
Article: HUMAN IMMUNOLOGY. 2014;75(2):170-175
Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia.
Hojjat-Farsangi M; Razavi SM; Sharifian RA; Shokri F
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626
Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: IMMUNOTHERAPY. 2013;5(7):703-715
Construction and characterization of a new chimeric antibody against HER2.
Amiri MM; Jeddi-Tehrani M; Kazemi T; Bahadori M; Maddah M; Hojjat-Farsangi M; Khoshnoodi J; Rabbani H; Shokri F
Article: CYTOKINE. 2013;62(3):439-445
Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia
Ghalamfarsa G; Jadidi-Niaragh F; Hojjat-Farsangi M; Asgarian-Omran H; Yousefi M; Tahmasebi F; Khoshnoodi J; Razavi SM; Saboor-Yaraghi AA; Rabbani H; Jeddi-Tehrani M; Shokri F
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(15_suppl):e22198
Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.
Hojat Farsangi M; Ghaemimanesh F; Daneshmanesh AH; Bayat A-A; Mahmoudian J; Jeddi-Tehrani M; Mellstedt H
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(15_suppl):7087
Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.
Daneshmanesh AH; Hojat Farsangi M; Moshfegh A; Khan S; Österborg A; Mellstedt H
Article: LEUKEMIA AND LYMPHOMA. 2013;54(4):843-850
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grander D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Osterborg A
Article: CANCER INVESTIGATION. 2013;31(2):121-131
Increased Frequency of CD8⁺ and CD4⁺ Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression
Jadidi-Niaragh F; Yousefi M; Memarian A; Hojjat-Farsangi M; Khoshnoodi J; Razavi SM; Jeddi-Tehrani M; Shokri F
Journal article: PLOS ONE. 2013;8(4):e61167
Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells (Retracted article. See vol. 17, 2022)
Hojjat-Farsangi M; Ghaemimanesh F; Daneshmanesh AH; Bayat A-A; Mahmoudian J; Jeddi-Tehrani M; Rabbani H; Mellstedt H
Article: PLOS ONE. 2013;8(10):e78339
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2013;62(1):51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865
Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein
Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frodin J-E; Wahren B; Mellstedt H; Ullenhag GJ
Article: LEUKEMIA. 2012;26(6):1348-1355
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi A-R; Hadavi R; Osterborg A; Shokri F; Rabbani H; Mellstedt H
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15_suppl):6557
Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.
Mellstedt H; Khan S; Vågberg J; Byström S; Schultz J; Hojat Farsangi M; Mansouri L; Danesh Manesh AH; Österborg A; Moshfegh A
Article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 2012;209(2):291-305
Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis
Du L; Peng R; Bjorkman A; de Miranda NF; Rosner C; Kotnis A; Berglund M; Liu C; Rosenquist R; Enblad G; Sundstrom C; Hojjat-Farsangi M; Rabbani H; Teixeira MR; Revy P; Durandy A; Zeng Y; Gennery AR; de Villartay J-P; Pan-Hammarstrom Q
Article: AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY. 2011;3(3):119-125
Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias.
Shabani M; Asgarian Omran H; Farsangi MH; Vossough P; Sharifian RA; Toughe GR; Razavi SM; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
Journal article: BLOOD. 2010;116(21):2413
Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)
Palma M; Kokhaei P; Hansson L; Hojat-Farsangi M; Choudhury AR; Osterborg A; Mellstedt H
Article: CANCER INVESTIGATION. 2010;28(7):717-725
Expression Profile of Galectin-1 and Galectin-3 Molecules in Different Subtypes of Chronic Lymphocytic Leukemia
Asgarian-Omran H; Forghani P; Hojjat-Farsangi M; Roohi A; Sharifian RA; Razavi SM; Jeddi-Tehrani M; Rabbani H; Shokri F
Article: CANCER SCIENCE. 2009;100(12):2346-2353
Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia
Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
Article: LEUKEMIA AND LYMPHOMA. 2009;50(12):2061-2070
Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia
Memarian A; Hojjat-Farsangi M; Asgarian-Omran H; Younesi V; Jeddi-Tehrani M; Sharifian RA; Khoshnoodi J; Razavi SM; Rabbani H; Shokri F
Article: INTERNATIONAL JOURNAL OF CANCER. 2008;123(9):2113-2119
Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia
Kazemi T; Asgarian-Omran H; Hojjat-Farsangi M; Shabani M; Memarian A; Sharifian RA; Razavi SM; Jeddi-Tehrani M; Rabbani H; Shokri F
Article: HUMAN IMMUNOLOGY. 2008;69(10):666-674
Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia
Hojjat-Farsangi M; Jeddi-Tehrani M; Amirzargar AA; Razavi SM; Sharifian RA; Rabbani H; Shokri F
Article: IRANIAN JOURNAL OF IMMUNOLOGY. 2008;5(1):25-35
Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression.
Hojjat Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Shamsian Khoramabadi A; Rabbani H; Shokri F
Article: LEUKEMIA AND LYMPHOMA. 2007;48(1):109-116
Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia
Farsangi MH; Jeddi-Tehrani M; Sharifian RA; Razavi SM; Khoshnoodi J; Rabbani H; Shokri F
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2005;19(6):706-711
Assessment of the immune system in 55 Iranian patients with vitiligo
Farrokhi S; Hojjat-Farsangi M; Noohpisheh MK; Tahmasbi R; Rezaei N
Visa fler

Alla övriga publikationer

Review: CELL COMMUNICATION AND SIGNALING. 2024;22(1):59
The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia
Barshidi A; Ardeshiri K; Ebrahimi F; Alian F; Shekarchi AA; Hojjat-Farsangi M; Jadidi-Niaragh F
Corrigendum: NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE. 2023;51:102690
Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240].
Masjedi A; Ahmadi A; Ghanee S; Malakotikhah F; Afjadi MN; Irandoust M; Kiani FK; Asl SH; Atyabi F; Hassannia H; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
Review: CELL COMMUNICATION AND SIGNALING. 2023;21(1):57
The prognostic and therapeutic potential of HO-1 in leukemia and MDS
Sadeghi M; Fathi M; Navashenaq JG; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Namdar A; Movasaghpour Akbari AA; Jadidi-Niaragh F
Review: EXPERT OPINION ON THERAPEUTIC TARGETS. 2022;26(12):1057-1071
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies
Sadeghi M; Khodakarami A; Ahmadi A; Fathi M; Navashenaq JG; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Akbari AAM; Jadidi-Niaragh F
Review: EXPERT OPINION ON THERAPEUTIC TARGETS. 2022;26(11):949-961
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions
Fathi M; Razavi S-M; Sojoodi M; Ahmadi A; Ebrahimi F; Namdar A; Hojjat-Farsangi M; Gholamin S; Jadidi-Niaragh F
Review: CANCER CELL INTERNATIONAL. 2022;22(1):241
The molecular biology and therapeutic potential of Nrf2 in leukemia
Khodakarami A; Adibfar S; Karpisheh V; Abolhasani S; Jalali P; Mohammadi H; Navashenaq JG; Hojjat-Farsangi M; Jadidi-Niaragh F
Review: IUBMB LIFE. 2021;73(5):726-738
T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
Review: INTERNATIONAL IMMUNOPHARMACOLOGY. 2021;90:107158
Oncostatin M: A mysterious cytokine in cancers
Masjedi A; Hajizadeh F; Dargani FB; Beyzai B; Aksoun M; Hojjat-Farsangi M; Zekiy A; Jadidi-Niaragh F
Review: IUBMB LIFE. 2020;72(10):2065-2079
Berberine: A novel therapeutic strategy for cancer
Samadi P; Sarvarian P; Gholipour E; Asenjan KS; Aghebati-Maleki L; Motavalli R; Hojjat-Farsangi M; Yousefi M
Review: BIOFACTORS. 2020;46(5):698-715
Exosome: From leukemia progression to a novel therapeutic approach in leukemia treatment
Gholipour E; Sarvarian P; Samadi P; Talebi M; Movassaghpour A; Motavalli R; Hojjat-Farsangi M; Yousefi M
Review: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 2020;20(7):758-767
CDK1 in Breast Cancer: Implications for Theranostic Potential
Izadi S; Nikkhoo A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Yousefi M; Jadidi-Niaragh F
Review: INTERNATIONAL IMMUNOPHARMACOLOGY. 2020;84:106471
Tumor associated macrophages in the molecular pathogenesis of ovarian cancer
Yousefzadeh Y; Hallaj S; Moornani MB; Asghary A; Azizi G; Hojjat-Farsangi M; Ghalamfarsa G; Jadidi-Niaragh F
Review: INTERNATIONAL IMMUNOPHARMACOLOGY. 2020;83:106446
Nanomedicine for improvement of dendritic cell-based cancer immunotherapy
Hashemi V; Farhadi S; Chaleshtari MG; Seashore-Ludlow B; Masjedi A; Hojjat-Farsangi M; Namdar A; Ajjoolabady A; Mohammadi H; Ghalamfarsa G; Jadidi-Niaragh F
Review: PATHOLOGY RESEARCH AND PRACTICE. 2020;216(5):152915
Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer
Salimifard S; Masjedi A; Hojjat-Farsangi M; Ghalamfarsa G; Irandoust M; Azizi G; Mohammadi H; Keramati MR; Jadidi-Niaragh F
Review: LIFE SCIENCES. 2020;247:117437
PD-L1/PD-1 axis as a potent therapeutic target in breast cancer
Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
Review: CLINICA CHIMICA ACTA. 2019;498:126-134
E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions
Hosseini SM; Okoye I; Chaleshtari MG; Hazhirkarzar B; Mohamadnejad J; Azizi G; Hojjat-Farsangi M; Mohammadi H; Shotorbani SS; Jadidi-Niaragh F
Review: MOLECULAR DIAGNOSIS AND THERAPY. 2019;23(4):467-487
S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy
Rostami N; Nikkhoo A; Ajjoolabady A; Azizi G; Hojjat-Farsangi M; Ghalamfarsa G; Yousefi B; Yousefi M; Jadidi-Niaragh F
Review: JOURNAL OF CELLULAR PHYSIOLOGY. 2019;234(7):9943-9955
Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis
Hosseini A; Masjedi A; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Anvari E; Jadidi-Niaragh F
Review: JOURNAL OF CELLULAR PHYSIOLOGY. 2019;234(5):5478-5487
The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer
Hashemi V; Masjedi A; Hazhir-karzar B; Tanomand A; Shotorbani SS; Hojjat-Farsangi M; Ghalamfarsa G; Azizi G; Anvari E; Baradaran B; Jadidi-Niaragh F
Review: EXPERT OPINION ON THERAPEUTIC TARGETS. 2019;23(2):127-142
CD73 as a potential opportunity for cancer immunotherapy
Ghalamfarsa G; Kazemi MH; Mohseni SR; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Review: BIOMEDICINE & PHARMACOTHERAPY. 2018;108:1415-1424
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
Masjedi A; Hashemi V; Hojjat-Farsangi M; Ghalamfarsa G; Azizi G; Yousefi M; Jadidi-Niaragh F
Review: JOURNAL OF CELLULAR PHYSIOLOGY. 2018;233(3):2032-2057
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
Kazemi MH; Raoofi Mohseni S; Hojjat-Farsangi M; Anvari E; Ghalamfarsa G; Mohammadi H; Jadidi-Niaragh F
Review: IMMUNOLOGY LETTERS. 2017;190:64-83
Nanoparticles and targeted drug delivery in cancer therapy
Bahrami B; Hojjat-Farsangi M; Mohammadi H; Anvari E; Ghalamfarsa G; Yousefi M; Jadidi-Niaragh F
Review: JOURNAL OF DRUG TARGETING. 2017;25(3):189-201
Recent advances in targeting mTOR signaling pathway using small molecule inhibitors
Roohi A; Hojjat-Farsangi M
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530
First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor
Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Review: CURRENT DRUG TARGETS. 2016;17(14):1687-1703
Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.
Shabani M; Hojjat-Farsangi M
Review: JOURNAL OF IMMUNOTOXICOLOGY. 2016;13(5):603-619
Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis
Ghalamfarsa G; Hojjat-Farsangi M; Mohammadnia-Afrouzi M; Anvari E; Farhadi S; Yousefi M; Jadidi-Niaragh F
Review: IRANIAN JOURNAL OF IMMUNOLOGY. 2016;13(3):148-166
Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15
Sheikhi A; Jafarzadeh A; Kokhaei P; Hojjat-Farsangi M
Review: TUMOR BIOLOGY. 2016;37(8):10021-10039
Mechanisms of tumor cell resistance to the current targeted-therapy agents
Khamisipour G; Jadidi-Niaragh F; Jahromi AS; Zandi K; Hojjat-Farsangi M
Review: JOURNAL OF DRUG TARGETING. 2016;24(5):373-385
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Review: JOURNAL OF DRUG TARGETING. 2016;24(3):192-211
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
Meeting abstract: BLOOD. 2015;126(23):2912
First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Review: TUMOR BIOLOGY. 2015;36(8):5727-5742
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy.
Bahrami B; Mohammadnia-Afrouzi M; Bakhshaei P; Yazdani Y; Ghalamfarsa G; Yousefi M; Sadreddini S; Jadidi-Niaragh F; Hojjat-Farsangi M
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458
The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Review: TUMOR BIOLOGY. 2015;36(2):543-556
Novel and emerging targeted-based cancer therapy agents and methods.
Hojjat-Farsangi M
Review: FUTURE ONCOLOGY. 2015;11(10):1567-1582
The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia.
Yousefi M; Movassaghpour AA; Shamsasenjan K; Ghalamfarsa G; Sadreddini S; Jadidi-Niaragh F; Hojjat-Farsangi M
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770
Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2014;15(8):13768-13801
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e13561
A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.
Mellstedt H; Daneshmanesh AH; Moshfegh A; Farsangl MH; Khan S; Mlkaelsson E; Vagberg J; Systrom S; Schultz J; Olin T; Ostorborg A
Meeting abstract: BLOOD. 2012;120(21):4583
Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia
Khan AS; Sandin A; Osterborg A; Hojjat-Farsangi M; Mellstedt H; Moshfegh A
Meeting abstract: BLOOD. 2012;120(21):1769
Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway
Daneshmanesh AH; Hojjat-Farsangi M; Sandin A; Khan AS; Moshfegh A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2012;48:S39
Investigation of TLR7/8 and 9 Agonists and CD40-ligand Costimulation on EBV Transformation of B Cells of Chronic Lymphocytic Leukemia
Younesi V; Nikzamir H; Hojjat-Farsangi M; Razavi SM; Shokri F
Conference publication: HAEMATOLOGICA. 2012;97:433
SMALL MOLECULES TARGETING ROR1 INDUCE SPECIFIC KILLING OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
Moshfegh A; Khan S; Vagberg J; Bystrom S; Hojat-Farsangi M; Mansouri L; Sandin A; Manesh AD; Osterborg A; Mellstedt H
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S642
Imbalanced Frequency of Regulatory T Cells in Different Subsets of Chronic Lymphocytic Leukemia
Jadidi-Niaragh F; Asgarian-Omran H; Yousefi M; Hojjat-Farsangi M; Razavi SM; Jeddi-Tehrani M; Shokri F
Conference publication: BLOOD. 2010;116(21):1001
Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)
Palma M; Kokhaei P; Hansson L; Hojat-Farsangi M; Choudhury AR; Osterborg A; Mellstedt H
Visa fler

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI